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A 38-year-old Chinese male with end-stage renal disease
secondary to immunoglobulin A nephropathy was admitted
with recurrent oral ulcers and rising serum creatinine 18
months after a successful renal transplantation. Primary
immunoglobulin A nephropathy was first diagnosed in 1996,
and his renal function deteriorated progressively, with serum
creatinine reaching 1040mmol/l in October 2005. His early post-
transplantation course was complicated by a mutant cytome-
galovirus infection that was successfully eradicated with high-
dose oral valganciclovir for 14 months. His renal function
remained stable, with a serum creatinine of 140mmol/l and
creatinine clearance of 80ml/min. His maintenance immuno-
suppressive therapy comprised of prednisolone 7.5mg daily and
tacrolimus 8mg daily, with trough tacrolimus levels between 10
and 12mg/l (therapeutic range 5–20).
In May 2007, he developed a small buccal aphthous ulcer
near his dental caries that failed to heal after dental
treatment. Biopsy of the non-healing ulcer showed chronic
inflammatory cell infiltrates with no evidence of neoplastic,
Epstein–Barr virus, cytomegalovirus, or tuberculous lesion.
He then developed abdominal pain and intermittent culture-
negative diarrhea. His body weight was reduced by 15 kg
within 6 weeks because of poor feeding attributed to
recurrent oral ulcers. Upper endoscopic examination was
normal. He was admitted in July 2007 following a further rise
in serum creatinine (171 mmol/l), with a reduced creatinine
clearance of 55ml/min and a fall in hemoglobin to 10.2 g/dl.
A whole-body fluordeoxy-glucose positron emission tomo-
graphy-computerized tomography scan was performed
(Figure 1).
What is the likely cause of recurrent oral ulcers and renal impairment?
http://www.kidney-international.org make your d iagnos i s
& 2009 International Society of Nephrology
SUV MA×—6.0
Functional Size—2.0×3.8×2.7CM
Figure 1 |Radiological imaging of the abdomen. (a) Positron emission
tomography (PET) scan and (b) PET-computerized tomography (PET-CT)
scan showing two focal hypermetabolic foci, 3.2 2.8 cm, in the terminal
ileum and cecum (arrows).
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The Diagnosis 7 Behcet’s disease (associated with IgA
nephropathy) and acute tacrolimus
nephrotoxicity
After admission, our patient developed tacrolimus nephrotoxi-
city requiring rapid dose reduction. A colonoscopy revealed two
huge, deep, irregular ulcers at the ileo-cecal valve. The
histopathology was compatible with Behcet’s disease (BD) or
Crohn’s disease. The liver function remained unchanged and the
CMVpp65 antigen was undetectable during the acute illness. He
also developed skin hyper-reactivity to subcutaneous injection.
His symptoms improved rapidly after treatment with
prednisolone (20mg/day) and sulfasalazine (4 g/day). Fol-
lowing the improvement of gastrointestinal symptoms, the
serum trough tacrolimus level became subtherapeutic, which
required rapid stepwise increase of tacrolimus to maintain
adequate immunosuppression (Figure 2). Three months after
the steroid and sulfasalazine treatment, his hemoglobin, renal
function, and body weight returned to baseline values.
Repeated colonoscopies were normal.
Our patient fulfilled the International Study Group criteria
for diagnosis of BD with oral ulcer and pathergy.1 Renal
involvement in BD, including amyloidosis, renal vascular
disease, glomerulonephritis, and interstitial nephritis, ranges
from 1 to 5%.2 Among different glomerulonephritides, only 22
cases of immunoglobulin A nephropathy (including this study)
have been reported in the literature.2–4 The clinical presentation
of our patient is unique, as his BD manifested only 11 years
after the diagnosis of immunoglobulin A nephropathy, whereas
the other 21 patients suffered from well-documented BD long
before renal symptoms appeared.
Gastrointestinal symptoms occur in 4.8% patients with
BD.5 Severe intestinal involvement is rare, and these lesions are
characterized by punch-out, discrete mucosal ulcerations as
seen in our patient. These are difficult to treat and are
associated with a high mortality rate. Our patient had two
deep ileo-cecal ulcers, which were likely to cause anemia,
malnutrition, and severe weight loss. Tacrolimus is absorbed
throughout the gastrointestinal tract and is almost completely
metabolized by the liver and the intestine before elimination
through the bile. The clinical and pharmacokinetic findings
strongly suggest that the enhanced tacrolimus absorption in
our patient associated with intestinal ulcers resulted in
tacrolimus nephrotoxicity, as there was no altered metabolism
due to liver impairment throughout his illness. Moreover,
healing of the ulcers was associated with rapid fall in the serum
tacrolimus level that required immediate dose adjustment.
Our study highlights the fact that altered pharmacokinetics
similar to that seen in patients with gastroenteritis could occur
in inflammatory bowel diseases.6 Hence, in patients with
organ transplantation, gastrointestinal disease may be asso-
ciated with altered intestinal drug absorption: blood levels
should be monitored closely to avoid drug toxicity or
inadequate immunosuppressive therapy.
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Figure 2 |Clinical features. Patient’s blood biochemistries, serum trough level of tacrolimus (FK506), tacrolimus dosage, and management
over the period of acute gut involvement of the Behcet’s disease.
1212 Kidney International (2009) 76, 1211–1212
make your d iagnos i s Kar Neng LAI et al.: IgA nephropathy and Behcet’s disease
